Prevention of chemotherapy-induced hemorrhagic cystitis

Prevention of chemotherapy-induced hemorrhagic cystitis refers to prophylactic intervention against diffuse, toxin-mediated inflammation and ulceration of the urinary bladder urothelium occurring as an adverse effect of antineoplastic therapy

Prevention of chemotherapy-induced hemorrhagic cystitis refers to prophylactic intervention against diffuse, toxin-mediated inflammation and ulceration of the urinary bladder urothelium occurring as an adverse effect of antineoplastic therapy

This toxic complication most commonly arises in oncology and hematopoietic stem cell transplantation populations exposed to oxazaphosphorine alkylating agents, predominantly cyclophosphamide and ifosfamide

This toxic complication most commonly arises in oncology and hematopoietic stem cell transplantation populations exposed to oxazaphosphorine alkylating agents, predominantly cyclophosphamide and ifosfamide

Pathophysiologically, hepatic metabolism of these agents yields acrolein, a renally excreted toxic metabolite that directly damages the bladder mucosa, inciting severe mucosal edema, microvascular ulceration, and downstream hemorrhage

Pathophysiologically, hepatic metabolism of these agents yields acrolein, a renally excreted toxic metabolite that directly damages the bladder mucosa, inciting severe mucosal edema, microvascular ulceration, and downstream hemorrhage

Clinically, the condition ranges from microscopic or gross hematuria to dysuria, urinary frequency, painful clot formation, and potentially life-threatening urinary tract obstruction

Clinically, the condition ranges from microscopic or gross hematuria to dysuria, urinary frequency, painful clot formation, and potentially life-threatening urinary tract obstruction

Clinically, the condition ranges from microscopic or gross hematuria to dysuria, urinary frequency, painful clot formation, and potentially life-threatening urinary tract obstruction